Our Work in Dermatology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
Atopic Dermatitis, Psoriasis
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in dermatology and those who are close to them.
Next Generation Biologics, Janssen’s Tremfya, Eli Lilly’s Taltz, and Novartis’ Cosentyx, Raising the Bar in Psoriasis Management – March 8, 2018
Growth of Sanofi-Regeneron’s Dupixent in Atopic Dermatitis May Be Facing Its First Plateau, while Pfizer’s Eucrisa Carves a Niche with Younger Patients– February 2, 2018
JAK Inhibitors Expected to Introduce Fierce Competition to Treatment Paradigms Across a Wide Range of Autoimmune Indications, Including Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, and Lupus – January 10, 2018
Fall Clinical Dermatology Conference